MITSUBISHI TANABE PHARMA CORPORATION

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Relapser Genotype 2 Hepatitis C Infected Patients

Phase 3

Completed

Conditions: Chronic Hepatitis C

Interventions: Drug: Ribavirin
Drug: Peginterferon alfa-2b

First Posted Date: 2011-11-06

Last Posted Date: 2014-11-02

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 108

Registration Number: NCT01466192

Locations: 🇯🇵
Toranomon Hospital, Minato-ku, Tokyo, Japan

A Confirmatory Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis

Phase 3

Completed

Conditions: Perennial Allergic Rhinitis

Interventions: Drug: Placebo
Drug: TAU-284

First Posted Date: 2011-08-30

Last Posted Date: 2015-12-14

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 490

Registration Number: NCT01425632

Locations: 🇯🇵
Reserch site, Kyusyu, Japan

Efficacy and Safety Study of TA-7284 in Patients With Type 2 Diabetes

Phase 3

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: TA-7284 Low
Drug: TA-7284 High
Drug: Placebo

First Posted Date: 2011-08-10

Last Posted Date: 2014-06-05

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 272

Registration Number: NCT01413204

Locations: 🇯🇵
Reserch site, Tohoku, Japan

Long-Term Safety Study of TA-7284 in Patients With Type 2 Diabetes Mellitus

Phase 3

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: TA-7284-Low
Drug: TA-7284-High

First Posted Date: 2011-07-06

Last Posted Date: 2014-06-06

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 1299

Registration Number: NCT01387737

Locations: 🇯🇵
Research site, Tohoku, Japan

Long-term Safety Study of MP-513 in Patients With Type 2 Diabetes

Phase 3

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: teneligliptin
Drug: glinide
Drug: alpha-glucosidase inhibitor
Drug: biguanide

First Posted Date: 2011-02-23

Last Posted Date: 2015-11-18

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 462

Registration Number: NCT01301833

Efficacy and Safety Study of MP-435 in Combination With Methotrexate (MTX) in Patients With Rheumatoid Arthritis

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Placebo + Methotrexate
Drug: MP-435(dose1) + Methotrexate

First Posted Date: 2010-06-14

Last Posted Date: 2014-10-13

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 112

Registration Number: NCT01143337

Locations: 🇯🇵
Investigational site, Osaka, Japan

Pharmacokinetic/Pharmacodynamic Study of MP-513 With Type 2 Diabetes Mellitus

Phase 3

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: MP-513
Drug: Placebo of MP-513

First Posted Date: 2010-02-22

Last Posted Date: 2013-04-09

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 99

Registration Number: NCT01072331

Efficacy and Safety Study of MP-513 in Combination With Thiazolidinedione in Patients With Type 2 Diabetes

Phase 3

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Placebo / Teneli (Teneligliptin) + pio (pioglitazone)
Drug: Teneli / Teneli + pio

First Posted Date: 2009-12-04

Last Posted Date: 2014-01-16

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 204

Registration Number: NCT01026194

An Efficacy, Safety, and Tolerability Study for TA-7284 in Patients With Type 2 Diabetes

Phase 2

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: TA-7284-Low
Drug: TA-7284-Low-middle
Drug: TA-7284-High-middle
Drug: TA-7284-High
Drug: Placebo

First Posted Date: 2009-12-01

Last Posted Date: 2014-06-05

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 383

Registration Number: NCT01022112

Locations: 🇯🇵
Research site, Tohoku, Japan

Monotherapy Study of MP-513 in Patients With Type 2 Diabetes

Phase 3

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Placebo
Drug: Teneligliptin 20 mg

First Posted Date: 2009-10-21

Last Posted Date: 2014-02-21

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 203

Registration Number: NCT00998881

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy